Large Vascular Disease Research Articles

Extraction and evaluation for anti-diabetic effects of some Indian plant extracts

Diabetes is a metabolic disease associated with changes in the structure and function of several biological systems. The main cause of tissue injury is persistent hyperglycaemia. The past 20 years have seen increased expansion of the harmful effects of persistent hyperglycaemia, even if peripheral neuropathy and small and large vascular disease can also be used to explain diabetes-related organ failure. Liophyllum decastes, Butea monosperma, and Opuntia dillenil fruit extracts were shown to pass phytochemical testing. The study findings of Butea Monosperma, Opuntia dillenil, and Liophyllum decastes distilled (150 mg/kg) and (300 mg/kg) on STZ-tempted DM rats were paired with Glibenclamide. The glucometer method, serum and urine analysis, as well as factors including body weight, food consumption, glucose levels, and biochemical analysis, were used to determine the blood sugar rankings. Liophyllum decastes fungus fruit, Opuntia dillenil Planned fruit, and distilled Butea monosperma leaves all have anti-diabetic properties for diabetics.

The factors influencing the efficiency of drug-coated balloons.

The drug-coated balloon (DCB) is an emerging percutaneous coronary intervention (PCI) device that delivers drugs to diseased vessels to decrease the rate of vascular stenosis. Recent clinical studies have demonstrated that DCBs tend to have both good safety and efficacy profiles, leading to extended application indications in the clinic, including in-stent restenosis (ISR) for metal stents such as drug-eluting stents (DESs), small vascular disease, bifurcation disease, large vascular disease, acute coronary syndrome (ACS), and high bleeding risk. However, some previous clinical data have suggested that DCBs performed less effectively than DESs. No studies or reviews have systematically discussed the improvement strategies for better DCB performance until now. Drug loss during the process of delivery to the target lesion and inefficient delivery of the coating drug to the diseased vascular wall are two key mechanisms that weaken the efficiency of DCBs. This review is the first to summarize the key influencing factors of DCB efficiency in terms of balloon structure and principles, and then it analyzes how these factors cause outcomes in practice based on current clinical trial studies of DCBs in the treatment of different types of lesions. We also provide some recommendations for improving DCBs to contribute to better DCB performance by improving the design of DCBs and combining other factors in clinical practice.

Acute Anterior Choroidal Artery Territory Infarction: A Retrospective Study

ObjectivesTo explore the clinical features, risk factors, etiopathogenesis, mechanism of progression, effect of intravenous thrombolysis therapy (IVT) and prognosis of acute ischemic stroke (AIS) in the anterior choroidal artery (AChA) territory. Patients and methodsA total of 113 AChA infarction patients were enrolled in the current study retrospectively. The demographic and clinical characteristics were collected and analyzed in all patients. The clinical characteristics were compared between clinical progression and no clinical progression groups, good and poor outcome groups, as well as with and without intravenous rt-PA groups. ResultsHemiparesis was the most common clinical manifestation (92.9%), followed by dyslexia (54.9%), hemianesthesia (43.4%) and other syndromes. Forty-nine patients (43.4%) suffered from clinical progression and showed a higher rate with multiple risk factors together than patients without clinical progression (30.6% vs.14.1%, P = 0.039). Moreover, more patients with progression were found with carotid plaques (73.5% vs. 51.6%, P = 0.018) or carotid artery stenosis (18.4% vs. 6.3%, P = 0.045) than patients without progression. 69.9% of patients got good prognosis at 6-months. In good prognosis group, the proportion of patients with atrial fibrillation, clinical progression and large infarct size were significantly lower than in poor prognosis group (1.3% vs. 11.8%, P = 0.047; 23.9% vs. 67.6%, P = 0.001; 15.2% vs. 38.2%, P = 0.007). No significant difference was found on rate of clinical progression and good prognosis between patients with and without IVT. ConclusionMotor deficits are the most frequent and typical symptoms in AChA infarcts. Although small artery disease was considered to be the important etiopathogenesis of the AChA infarcts, large vascular disease may be associated with clinical progression in AChA infarcts. Additionally, prognosis of AChA infarcts is correlated with clinical progression, infarct size and atrial fibrillation. IVT does not seem to prevent the clinical progression and improve prognosis of AChA infarcts.